Skip to content

Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)

Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03321136
Acronym
LDR
Enrollment
16
Registered
2017-10-25
Start date
2017-11-28
Completion date
2019-07-11
Last updated
2019-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Serotonin receptors, especially the 5HT2A receptor, are thought to be involved in the effects of various recreationally used psychedelic substances such as LSD. LSD potently stimulates the 5-HT2A receptor but also 5-HT2B/C, 5-HT1 and dopaminergic receptors. LSD induces acute transient alterations in waking consciousness including visual perceptual alterations, audio-visual synesthesia, derealization and depersonalization. LSD has therefore been used as experimental tool (psychotomimetic) in modern psychiatric research to study psychotic-like states and model psychosis in healthy subjects \[1-5\]. However, the dose-effects of 5-HT2A receptor stimulation by LSD has not yet been studied. Additionally, there is still very limited data to what extent the 5HT2A receptor contributes to LSD's effects and its role in the mediation of the full response to LSD at a high dose is unclear. A recent experimental human study showed the 5-HT2A receptor antagonist ketanserin fully blocked the subjective effects of a moderate dose of 100 µg of LSD \[6\]. But, whether the effects of a high 200 µg oral dose of LSD can be blocked by the selective pharmacological 5-HT2A antagonist ketanserin remains to be tested to confirm the critical role of the 5-HT2A receptor in more pronounced alterations of consciousness and perception. The present study therefore explores the role the 5-HT2A receptor in LSD-induced altered states of consciousness using escalating doses of LSD and the 5-HT2A receptor blocker ketanserin administered before a high dose of LSD.

Interventions

DRUGLSD

0.025 mg LSD per os, single dose

DRUGPlacebo

Capsules containing mannitol looking identical to the other drugs.

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age between 25 and 65 years. 2. Understanding of the German language. 3. Understanding the procedures and the risks associated with the study. 4. Participants must be willing to adhere to the protocol and sign the consent form. 5. Participants must be willing to refrain from taking illicit psychoactive substances during the study. 6. Participants must be willing to drink only alcohol-free liquids and no coffee, black or green tea, or energy drink after midnight of the evening before the study session, as well as during the study day. 7. Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration. 8. Women of childbearing potential must have a negative pregnancy test at the beginning of the study. Pregnancy tests are repeated before each study session. 9. Women of childbearing potential must be willing to use double-barrier birth control 10. Body mass index 18-29 kg/m2.

Exclusion criteria

1. Chronic or acute medical condition 2. Current or previous major psychiatric disorder 3. Psychotic disorder in first-degree relatives 4. Illicit substance use (with the exception of cannabis) more than 10 times or any time within the previous two months. 5. Pregnant or nursing women. 6. Participation in another clinical trial (currently or within the last 30 days) 7. Use of medications that may interfere with the effects of the study medications (any psychiatric medications) 8. Tobacco smoking (\>10 cigarettes/day) 9. Consumption of alcoholic drinks (\>10/week)

Design outcomes

Primary

MeasureTime frameDescription
Altered states of consciousness18 monthstotal 5D-ASC score (5-Dimensional Altered States of Consciousness Rating Scale)

Secondary

MeasureTime frameDescription
Subjective effects18 monthsVAS (Visual analog scales)
Psychotomimetic effects18 monthsESI scale (Eppendorf Schizophrenia Inventory)
Mystical-type experiences18 monthsMS scales (Mysticism scale)
Autonomic effects18 monthsBlood pressure

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026